PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis
← catalyst calendarNCT06422871 · readout in 313 d
Sponsored by Merit Medical Systems, Inc. (industry) · MMSI — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
100estimated
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-28 | actual | When the study began enrolling |
| Primary completion | 2027-06-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-28 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- End Stage Renal Disease
- Hemodialysis Access Failure
Intervention
- Device: HeRO® Graft System or Super HeRO® System
Primary outcome
what the primary-completion date above is the date OFComposite Endpoint
measured 6 months
Permalink · MMSI's whole pipeline · Catalyst calendar · Every registered study · What changed